Corcept shares tumbled over 35% after the FDA said it needs more evidence to assess the benefit-risk profile of relacorilant for Cushing’s syndrome. The agency acknowledged that the GRACE trial met its main goal but was not ready to support approval, prompting a sharp sell-off in the stock.